ALKS ALKERMES PLC Investments/Divestments 8-K Filing 2024 - Positive Results Announcement Alkermes plc announced positive results from a phase 1b study of its novel drug ALKS 2680 for narcolepsy and hypersomnia.Get access to all SEC 8-K filings of the ALKERMES PLC